Inappropriate activation of the Wnt/b-catenin signaling has been implicated in the development of hepatocellular carcinoma (HCC), but exactly how b-catenin works remains to be elucidated. To identify, in vivo, the target genes of b-catenin in the liver, we have used the suppression subtractive hybridization technique and transgenic mice expressing an activated b-catenin in the liver that developed hepatomegaly. We identified three genes involved in glutamine metabolism, encoding glutamine synthetase (GS), ornithine aminotransferase (OAT) and the glutamate transporter GLT-1. By Northern blot and immunohistochemical analysis we demonstrated that these three genes were specifically induced by activation of the b-catenin pathway in the liver. In different mouse models bearing an activated bcatenin signaling in the liver known to be associated with hepatocellular proliferation we observed a marked upregulation of these three genes. The cellular distribution of GS and GLT-1 parallels b-catenin activity. By contrast no up-regulation of these three genes was observed in the liver in which hepatocyte proliferation was induced by a signal-independent of b-catenin. In addition, the GS promoter was activated in the liver of GS +/LacZ mice by adenovirus vector-mediated b-catenin overexpression. Strikingly, the overexpression of the GS gene in human HCC samples was strongly correlated with b-catenin activation. Together, our results indicate that GS is a target of the Wnt/b-catenin pathway in the liver. Because a linkage of the glutamine pathway to hepatocarcinogenesis has already been demonstrated, we propose that regulation of these three genes of glutamine metabolism by b-catenin is a contributing factor to liver carcinogenesis.
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Introduction
Hepatocellular carcinoma (HCC) is a cancer that is becoming increasingly common worldwide (Bosch et al., 1999) . The prognosis is rather poor and although the major risk factors, chronic hepatitis B (HBV) or C (HCV) infection and exposure to hepatocarcinogens like aflatoxin B1, are well characterized, the way in which the carinogenesis develops is still unclear. Several genetic alterations have been implicated in at least three carcinogenesis pathways, p53, RB and the Wnt/bcatenin signaling pathway (de La Coste et al., 1998; Buendia, 2000, for review) . This last pathway appears to be one that is most frequently altered in human HCC and concerned about 30 -40% of human HCC and more than 80% of the hepatoblastomas (Buendia, 2000) . Mutations affecting two partners of the b-catenin signaling have been found so far. Activating mutations of the b-catenin gene occur mainly in HBV-negative tumors (Laurent-Puig et al., 2001) and in more than 50% of hepatoblastomas (Koch et al., 1999; Wei et al., 2000) . Inactivating mutations of the axin 1 gene are less frequent and are in particular found in HBV-positive tumors (Laurent-Puig et al., 2001; Satoh et al., 2000) .
Characterization of the downstream targets activated in response to deregulation of the Wnt/b-catenin in the liver is thus an important challenge for both fundamental research and the development of therapies. Several target genes of the b-catenin signaling may have a function in carcinogenesis, like c-myc or cyclin D1 (He et al., 1998; Tetsu and McCormick, 1999) , but our recent results obtained with transgenic mice strongly suggest that they do not play a key role in the liver. Indeed, we have shown that neither the c-myc nor cyclin D1 genes are overexpressed in the liver of transgenic mice expressing an oncogenic form of b-catenin, although the liver of these mice becomes strongly hyperplastic, associated with marked hepatocellular proliferation (Cadoret et al., 2001) .
The present in vivo study was carried out to identify target genes of the Wnt/b-catenin signaling pathway activated in the liver. We used a PCR-based cDNA subtraction strategy, suppression subtractive hybridization (SSH) using RNA isolated from either the hyperplastic liver of transgenic mice expressing an oncogenic form of b-catenin or from the liver of control non-transgenic mice. We were able to identify genes that were differentially expressed, and thus could be relevant to hepatocarcinogenesis. We isolated three genes, all three belonging to the glutamine metabolism pathway, the genes for glutamine synthetase (GS), ornithine aminotransferase (OAT) and glutamate transporter GLT-1. These genes were all specifically induced in different mouse models bearing a deregulated b-catenin signaling in the liver. We found that b-catenin signaling induced GS promoter activity in vivo indicating that GS is a liver target gene of the Wnt pathway. We also observed a strong correlation between activated bcatenin and GS overexpression in human HCC samples.
Results

Isolation of GS, OAT and GLT-1 by SSH
Target genes of b-catenin signaling in the liver were identified by a PCR-select cDNA subtraction analysis using the hyperplastic liver of the DN131b-catenin transgenic mice and the liver of control non-transgenic mice (Cadoret et al., 2001) . Differential screening of 3000 clones gave 170 cDNAs having a strong positive signal after hybridization with the subtracted cDNA probe from DN131b-catenin transgenic liver. They were sequenced and matched with 23 known genes or expressed sequence tags. Northern blotting was used to confirm that the transcripts were differentially expressed. We focused on three cDNAs whose expression was dramatically increased in the liver of DN131b-catenin transgenic mice; they all belong to the glutamine pathway and encode GS, OAT and GLT-1 (Figure 1a ). Increased expression of the GLT-1 and GS genes was confirmed by Western blots (Figure 1b) .
Coordinate up-regulation of GS, OAT and GLT-1 genes in response to activation of b-catenin signaling in the liver We confirmed that these three genes were regulated by activation of b-catenin signaling in the liver by analysing their expression in two other mouse models that also have a deregulated hepatic b-catenin signaling. One was the liver tumors developed in PK/c-myc transgenic mice in which the b-catenin gene frequently bears activating mutations (de La Coste et al., 1998) . We analysed RNA samples from several tumors carrying an activating mutation in the b-catenin gene and from the adjacent nontumoral liver. As expected, Figure 1 The GS, OAT and GLT-1 genes as potential b-catenin targets in mouse liver. (a) GS, OAT and GLT-1 gene expression in DN131b-catenin transgenic mice. RNA from non transgenic (NT) and DN131b-catenin transgenic liver (DN131) were analysed by Northern blotting. Blots were standardized with a ribosomal probe R45. (b) Western blot analysis of liver from DN131b-catenin transgenic mice. Total cell extracts were analysed by SDS -PAGE and immunoblotted with anti-GS or GLT-1 specific antibodies. The blot was reprobed with antibody against a-tubulin to ensure equal protein loading. Since no specific antibody against murine OAT was available, we couldn't check the level of the OAT protein in the liver of these mice. all three genes GS, OAT, and GLT-1, were strongly activated in the tumors and barely detectable in the nontumoral part of the liver (Figure 1c ). The second model involved a recombinant adenovirus strategy to deliver an oncogenic form of b-catenin to the liver, since hepatocytes are known to be readily transduced (Ferry and Heard, 1998) . Mice were intravenously injected with an adenovirus encoding an activated bcatenin Adb-catS37A, or control adenoviruses, AdLacZ, AdGFP and killed 12, 24, 48 and 120 h after injection. Transgene expression was detectable 24 h post injection (Figure 4a and data not shown). Thus, this system allowed us to study the early effects of bcatenin signaling in the liver. Northern blot analysis indicated that the expression of all three genes GS, OAT, and GLT-1, were upregulated in parallel in the liver of mice 48 h after the injection of Adb-catS37A.
No such upregulation occurred in the liver of mice injected with the control adenoviruses encoding LacZ or GFP ( Figure 1d ).
To determine if the upregulation of the three genes, GS, OAT, GLT-1 was a targeted response to b-catenin signaling in the liver or a general response to an oncogenic stimulus, we analysed the expression of these genes in another transgenic model in which liver tumorigenesis was independent of b-catenin activation. Indeed, b-catenin mutations are absent in hepatocellular carcinomas of SV40 large T antigen transgenic mice (Umeda et al., 2000) . We thus used the ASV mouse model in which liver tumors are induced by SV40 T antigen (Bennoun et al., 1998) . No induction of these three genes was observed in the tumoral liver of ASV mice as compared to the normal liver ( Figure  2 ).
Expression of GS and GLT-1 in the liver correlates with activation of b-catenin signaling in the liver
The distribution of GS in the post-natal liver is striking. GS activity is restricted to a small population of hepatocytes surrounding the central vein (Gebhardt and Mecke, 1983) . Our results suggest that the heterogeneous distribution of this gene might be altered in the liver of mice carrying an activated bcatenin signaling, since b-catenin activity is induced in most of the hepatocytes in the DN131b-catenin mice (Cadoret et al., 2001) and in the liver tumors of PK/cmyc mice (de La Coste et al., 1998) . This was the case. While GS is restricted to pericentral hepatocytes in the normal liver, most of the hepatocytes in the liver lobule of the DN131b-catenin mice were stained by anti-GS antiserum ( Figure 3a) . We then analysed the distribution of GS in liver tumors from PK/c-myc transgenic mice. As shown on Figure 3b , the adjacent nontumoral tissue showed a staining pattern similar to that of normal liver, but tumoral tissue was covered by a uniform staining for GS throughout the tumor that parallels cytosolic and, less frequently, nuclear accumulation of b-catenin, indicative of the b-catenin signaling activation (Polakis, 2000) .
The immunostaining with the anti-GLT-1 antibody was highly informative. Until now the cellular distribution of GLT-1 in the liver was unknown. We observed that it was restricted to the perivenous region in the normal liver like GS. Interestingly we observed that similarly to GS, GLT-1 expression was diffuse in all the liver lobule of the DN131b-catenin mice and in the tumoral liver of the PK/c-myc mice (Figure 3a ,b). We failed to perform similar immunostaining for the OAT gene due to the lack of a specific antibody. However it is known that GS and OAT colocalized in the perivenous region in normal liver (Kuo and Darnell, 1991) . In view of all of our present data, we can hypothesize that OAT follows the same pattern of distribution than GS and GLT-1, both in normal and b-catenin-activated liver.
Lastly, we analysed by immunohistochemistry the distribution of GS in Adb-catS37A-infected livers. In accordance with the data obtained by Northern blotting (Figure 1d) , only a few GS-positive hepatocytes outside the perivenous region were observed at 24 h after adenovirus infection (Figure 4c ), GS expression was markedly increased in most of the hepatocytes of the liver lobules at 48 h and 120 h post-infection ( Figure  4f ,i). The analysis of the proliferative response showed that the increase in b-catenin expression preceded that of hepatocellular proliferation. Most of the hepatocytes expressed the b-catenin oncogenic form at 24 h ( Figure  4a ) while the hepatocyte proliferation revealed by Ki-67 staining was only obvious at 48 h (Figure 4e ). This proliferative response results both from activation of the b-catenin pathway and from the cytotoxic effect of the adenovirus. But it is interesting to note that in AdbcatS37A-infected livers, the strong increase in hepatocellular proliferation was associated with GS overexpression (Figure 4e ,h,f,i) while in control liver infected with the adenovirus encoding GFP, although the hepatocyte proliferation due to the cytotoxic effect of the adenovirus was marked (Figure 4k ), the cellular distribution of GS was unchanged, being restricted to the perivenous region (Figure 4l ). In these mice no activation of the b-catenin signaling was observed (data not shown). Accordingly, our previous work has shown that the liver tumors developed in PK/c-myc mice have Figure 2 Expression of GS, OAT and GLT-1 genes in hyperproliferative mouse liver of SV40 large T antigen transgenic mice. RNA prepared from non-transgenic liver (NT) and tumoral liver of ASV mice was analysed by Northern blotting. Blots were hybridized with GS, OAT or GLT-1 probe and standardized with ribosomal R45 probe b-catenin target genes in the liver A Cadoret et al a high proliferative activity and bear a deregulated bcatenin signaling (de La Coste et al., 1998 we showed in this present study that these liver tumors express GS and GLT-1 (Figure 3 ). On the other hand, in the ASV mice the liver tumors are induced by SV40 T antigen, these tumors present a high proliferative activity known to be independent of b-catenin (Bennoun et al., 1998; Umeda et al., 2000) and no induction of GS and GLT-1 was observed (data not shown).
Altogether, these results thus show that overexpression of GS and GLT-1 is associated with activation of b-catenin signaling in the liver and does not constitute a nonspecific response to hepatocellular proliferation.
In vivo up-regulation of GS by b-catenin
To examine the regulation of the GS gene by b-catenin in vivo, we used heterozygous GS +/LacZ knockout mice carrying the LacZ gene in the GS gene locus (W Lamers, unpublished data). In this model, the LacZ gene is under the control of the GS promoter and b-galactosidase staining reflects the GS promoter activity. The GS +/LacZ mice were injected with the AdGFP or the Adb-catS37A adenovirus and their livers were collected 5 days postinjection. As expected, b-galactosidase staining was restricted to the perivenous region in the control AdGFP-infected livers in accordance with the expression pattern of the GS endogenous gene ( Figure 5 ). On the other hand, in the Adb-catS37A-injected mice we observed heterogeneous staining in most of the hepatocytes of the liver lobule that correlates with the expression of the oncogenic form of b-catenin ( Figure 5 ). This result indicates that the GS promoter was activated by bcatenin signaling in the liver and demonstrates that GS is indeed a target gene of b-catenin.
Correlation between the upregulation of GS, OAT and GLT-1 and b-catenin activity in human HCC
We have previously reported that deregulation of bcatenin signaling frequently occurs in human HCC (de , 1998) . GS is upregulated in a subset of HCC (Christa et al., 1994; Osada et al., 2000) , but the reasons for the overexpression of the GS gene are presently unknown. This observation prompted us to determine whether GS overproduction was specifically associated with b-catenin activation in human HCC. We therefore immunostained a large number of HCC for b-catenin and GS using a tissue microarray approach (TMA). We found a strong correlation between activation of the b-catenin signaling and upregulation of the GS gene ( Figure 6a ). All of the tumors having cytosolic and/or nuclear b-catenin displayed an overexpression of the GS gene. By contrast, most of the HCC that showed a membranous b-catenin staining did not reveal an up-regulation of GS (Figure 6a ). However, we also observed in some cases, overexpression of the GS gene that was not associated with b-catenin, suggesting that other mechanisms, still unknown, can stimulate GS gene expression.
To determine whether the activation of b-catenin signaling in human HCC samples was correlated with an increase in the level of expression of GS, OAT and GLT-1 genes, we used quantitative RT -PCR with another batch of tumor samples screened for b-catenin mutations. The ratios of gene expression between the tumoral tissue and the adjacent nontumoral tissue were analysed (Figure 6b ). The GS gene was overexpressed more than twofold in all the HCC samples carrying an activating mutation of the b-catenin gene (7/7) and in many of the others samples (8/15), in agreement with the TMA assay. The OAT and GLT-1 genes were also frequently overexpressed in HCC tissues (9/22 and 8/22 respectively), but only in four of the seven cases with mutated b-catenin. Wilcoxon analyses indicated that the induction of the GS gene was significantly correlated with b-catenin activation in HCC samples (P50.01), whereas induction of the OAT (P=0.45) and GLT-1 (P=0.09) genes was not. The lack of positive correlation for the OAT and GLT-1 genes could be due to the fact that HCC are heterogeneous tumors. However, it is interesting to note that three of the seven cases of tumors with mutated b-catenin showed a coordinate strong overexpression of the GS, OAT and GLT-1 genes. No coordinate overexpression of these three genes was observed in the b-catenin negative tumors (Figure 6b ).
Therefore these results point to a significant correlation between activation of the b-catenin signaling pathway in human HCC samples and up-regulation of GS, and at least for the strongest overexpressions of OAT and GLT-1.
Discussion
Our results demonstrate that overexpression of the three genes encoding glutamine synthetase, ornithine aminotransferase and the glutamate transporter GLT-1 that are involved in the glutamine metabolism, are associated with activation of b-catenin signaling in the liver. (1) Northern blotting studies showed that GS, OAT and GLT-1 are all strongly upregulated in the liver of three mouse models with deregulated liver b- (Kuo and Darnell, 1991) indicate that these three genes are expressed in a small subpopulation of hepatocytes surrounding the terminal hepatic veinules in normal liver. We show that overexpression of the GS and GLT-1 genes could be induced in the other part of the hepatic lobule in response to b-catenin activation. There is a clear correspondence between the distribution of GS and GLT-1 (and probably OAT) and activation of bcatenin signaling in the liver. (3) These three genes are not upregulated in response to stimulation of hepatocyte proliferation that is independent of b-catenin, as is the case in hepatic tumors induced by transgenic SV40 T antigen without mutation in the b-catenin gene (Umeda et al., 2000) , and in mice injected with control adenovirus encoding GFP. Altogether these results demonstrate that overexpression of these three glutamine metabolism genes is specifically associated with activation of b-catenin signaling in the liver and is not a nonspecific response associated with hepatocyte proliferation. Accordingly, GLT-1 has been shown to be induced in response to the activation of Wnt-1 in C6 glioma cells (Palos et al., 1999) . The experiment using the GS +/LacZ mice clearly showed that, in the liver, the activity of the GS promoter is up-regulated by b-catenin in vivo, and thus demonstrates, that GS is a target gene of b-catenin in the liver. Such experiments could not be carried out for the OAT and GLT-1 genes, but all of our results together with published data strongly suggest that these three genes are under similar transcriptional control and are likely to be target genes of b-catenin signaling in the liver. Yet, it is not clear whether these genes are direct or indirect targets. The GS, OAT and GLT-1 genes become active 48 h after infection by an adenovirus encoding an activated b-catenin form while b-catenin expression is clearly detected at 24 h. Thus, these genes could be upregulated either by a direct bcatenin-dependent transcriptional mechanism or through a b-catenin signaling that turns on a transcription factor, which in turn coregulates these three genes. In any case, we were unable to directly stimulate ex vivo, by transient transfection, constructs directed by 5' flanking sequences of both human GS and OAT genes (data not shown), which could rather argue for the second hypothesis.
Whatever mechanism is responsible for the bcatenin-dependent induction of these genes involved in the glutamine metabolism, our results suggest that this phenomenon could be involved in the proliferative response of the liver to b-catenin. Indeed we have demonstrated that expression of an oncogenic mutant of b-catenin in DN131b-catenin mice led to a marked hepatomegaly. Similar results have been obtained by a recent study and confirmed that activation of b-catenin in the liver led to hepatocyte hyperplasia (Harada et al., 2002) . Although no hepatic tumors could be observed in the DN131b-catenin mice probably because of the early death of these transgenic mice, this event is likely to be preneoplastic, fostering additional genetic events which, together with dysregulation of b-catenin signaling, may lead to hepatocyte transformation. The role of these three genes of the glutamine metabolism in the altered growth of the hepatocyte is presently unknown and we can only hypothesize. Glutamine is critical for the growth of proliferative cells, supporting protein and nucleotide synthesis and providing a major source of energy (Kovacevic and McGivan, 1983) . GLT-1 transports glutamate inside the cell and OAT can generate glutamate from ornithine. The glutamate produced by these two pathways could then be used as a substrate by GS to synthetize glutamine. Thus, the increased activities of OAT, GLT-1 and GS could make the cell independent of any glutamine supply and confer a growth advantage to the cell. The relevance of our data are highlighted by the fact that a linkage between the glutamine pathway and hepatocarcinogenesis has already been described (Gebhardt and Williams, 1995, for review) . In rodents, GS-positive hepatocarcinoma foci also tend to grow faster than GS-negative foci, the GS-positive phenotype is associated with larger tumors, implying that GS activity confers a growth advantage on these tumors (Gebhardt and Williams, 1995) . Moreover, in humans, GS and OAT are upregulated in a subset of HCC (Christa et al., 1994; Miyasaka et al., 2001; Osada et al., 2000) . Finally, the importance of the glutamine metabolism for hepatocellular proliferation is also emphasized by the human data that suggest that another(s) pathway(s), different from the Wnt/b-catenin pathway, could also regulate GS gene expression. Since overexpression of the GS gene appears to be primordial for an independent glutamine supply, it is not surprising that GS could be regulated by more than one signaling pathway.
Although an implication of the glutamine metabolism in liver carcinogenesis through an overexpression of GS was already observed, the molecular mechanism responsible for the up-regulation of GS was still unknown. Our results provide genetic evidence that activation of b-catenin induced the expression of GS in liver. Together with the data obtained for the OAT and GLT-1 genes our study strongly suggests a link between activation of the b-catenin signaling and the control of glutamine metabolism.
Materials and methods
Suppression subtractive hybridization (SSH)
We generated cDNA from 1 mg poly(A) + RNA isolated from the liver of a DN131b-catenin transgenic mouse (tester) and a nontransgenic littermate (driver) using the SMART TM PCR cDNA Synthesis kit (Clontech). SSH was performed with the PCR-Select TM cDNA Subtraction kit (Clontech) according to the manufacturer's protocol. The subtracted cDNA library was sublconed into T/A cloning vector pT-Adv (Clontech) and transformed to ELECTROMAX DH10B cells (Life Technologies). The library was plated on LB-ampicillin plates and incubated at 378C overnight. Two replicas were made using Hybond N + nylon membranes. For differential screening, replica filters were hybridized with 32 P-labeled subtracted tester and driver probes. Plasmid DNA from differentially expressed clones was purified and sequenced. Blast search was used to analyse sequence homologies in the gene database.
Adenoviral in vivo gene transfer
Adenovirus constructs AdGFP, AdLacZ and Adb-catS37A used were previously described (Young et al., 1998) . B6D2/F1 mice were intravenously injected with 5610 9 plaque-forming units of AdGFP, AdLacZ or Adb-catS37A, and were sacrificed 12, 24, 48 and 120 h after adenovirus injection.
Northern blotting
Total RNA was extracted from frozen liver by the guanidium thiocyanate single-step procedure and an aliquot (10 mg) was electrophoresed through 1% agarose-6% formaldehyde gel. The RNAs were transferred to Hybond N + membranes and hybridized with the corresponding 32 P-labeled probes.
Western blotting
Tissues were homogenized in Laemmli buffer (1 : 10 w/v). 30 mg total protein were separated by 10% SDS -PAGE and transferred to a nitrocellulose membrane. GLT1 and GS proteins were detected using polyclonal anti-glutamate transporter GLT-1 (Chemicon International, Inc.) or monoclonal anti-glutamine synthetase (Transduction Laboratories) antibodies. The signals were visualized with the ECL detection system.
Immunohistochemistry
Immunostaining was performed on 5 mm sections of formalin-fixed, paraffin-embedded liver. Sections were incubated with specific antibodies for 1 h. The primary antibodies used were polyclonal anti-GLT1 (kindly provided by Dr Watanabe, Japan, 1/250), monoclonal anti-GS (1/200), monoclonal anti-b-catenin (Transduction laboratories, 1/ 500), polyclonal anti-GFP (Clontech, 1/50) and polyclonal anti-HA (Roche, 1/400). GS, b-catenin, GFP and HA were visualized using the indirect immunoperoxidase protcol (Vectastain ABC kit, Vector). GLT-1 immunostaining was visualized with a horseradish peroxidase-coupled anti-guinea pig antibody (Dako). Ki-67 was immunodetected as previously described (Cadoret et al., 2001) . A tissue-microarray (TMA) block containing 105 HCC was prepared as previously reported (Kallioniemi et al., 2001) . Only 90 tumoral tissues could be analysed after immunohistochemistry due to insufficient material or a technical problem.
b-galactosidase staining
This experiment was conducted on GS +/LacZ mice. The coding region of the glutamine synthetase gene was replaced by a b-galactosidase neomycine fusion gene by homologous recombination, resulting in the production of GS +/LacZ mice (Y He, MA Roon, and WH Lamers, in preparation). Frozen sections of liver were fixed in 0.2% glutaraldehyde, 1.5% formaldehyde, 0.1 M phosphate buffer pH 7.3, 0.5 mM EGTA, 2 mM MgCl 2 on ice for 5 min, rinsed three times in phosphate-buffered saline (PBS) and incubated in b-galactosidase staining solution (5-bromo-4-chloro-3-indoyl-b-Dgalactopyranoside [X-gal] 1 mg/ml, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 , 0.01% sodium deoxycholate, 0.02% Nonidet P-40 in 0.1 M phosphate buffer pH 7.3) at 378C overnight. Then they were washed twice in PBS at room temperature for 5 min each, rinsed in distilled water and counterstained in eosin for 1 min.
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Real-time RT -PCR
PCR reactions were performed using a LightCycler and the LightCycler-FastStart DNA Master SYBR Green I kit (Roche Diagnostics). The relative target gene expression was normalized on the basis of its 18S content and to a calibrator consisting of one of our tissue samples that contained the smallest amount of target gene mRNA (Cadoret et al., 2001) . Each primer was placed in a different exon to avoid amplifying contaminating genomic DNA. The sequences were as follows, human OAT gene: OATF: 5'-CACTGGAGCGTGCTCTTC-3', OATR: 5'-AAAGAG-AACCTGGTGCCT-3', human GLT1 gene: GLT1F: 5-GT-CATTCTGGTCTTGGCT-3', GLT1R: 5'-GGACAAGGTT-TTCAGGGA-3', human GS gene: GSF: 5'-AAGTGTGTG-GAAGAGTTGCC-3', GSR: 5'-TGCTCACCATGTCCA-TTATC-3', 18s gene: 18SF: 5'-GTAACCCGTTGAACCC-CATT-3', 18SR: 5'CCATCCAATCGGTAGTAGCG-3'.
Experiments were performed with duplicates for each data point.
